7. Ino Y, Kubo T, Tanaka A, et al. Difference of culprit lesion morphologies between ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. JACC Cardiovasc Interv 2011;4:76-82. 8. Jia H, Abtahian F, Aguirre AD...
14. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of th...
7. Ino Y, Kubo T, Tanaka A, et al. Difference of culprit lesion morphologies between ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. JACC Cardiovasc Interv 2011;4:...
在PCI或最后一次血管造影后,两组患者的TIMI-3血流等级相似,均≈87%(P=0.74);药物-侵入性策略组和pPCI组ST段抬高恢复≥50%者分别占85.2%和78.4%(P=0.05),且两组在30天达到临床疗效复合终点的比例相似(药物-侵入性策略组12.8% vs. pPCI组 13.3%),相对危...
[2] O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the management of ST-Elevation myocardial infarction: Executive Summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2013,127: 529...
1、stemi高血栓负荷患者介入治疗策略经皮冠状动脉介入治疗(percutanous coronary intervention, pci)己成 为急性 st 段抬高心肌梗死(st segment elevation myocardial infarction, stemi)患者的首选治疗方式,但梗死相关hll管屮固有的破裂斑块、血栓、 异常激活的血小板粘附和聚集功能,及与pci术相关的高凝因素,更重要 的是...
A STEMI, or ST elevationmyocardial infarction, is a heart attack that occurs when a major artery feeding into the heart is completely blocked. This changes the blood flow to the organ and the electrical current in the lower chambers.
百度试题 题目ST段抬高型心肌梗死(STEMI)的英文全称是? A.ST-elevation myocardial infarctionB.ST-segment elevation myocardialC.ST-segment elevation myocardial infarctionD.ST-segment myocardial infarction相关知识点: 试题来源: 解析 C
在过去30年里,与非ST段抬高型心肌梗死(NSTEMI)相比,美国 ST段抬高型心肌梗死(STEMI) 的住院人数显著下降。据报道,因急性冠脉综合征(ACS)入院就诊的患者中,38%存在STEMI。随着治疗药物及相关技术的进步,STEMI患者的预后结果已有所改善。不过,STEMI的整体发病率及死亡率仍然较高,且给医疗体系带来了较重的经济负担,...
心源性休克(CS)是ST段抬高型心肌梗死(STEMI)患者的主要死因。尽管β-受体阻滞剂是冠心病二级预防中的关键药物,但它对血流动力学的不良影响限制了其在CS患者中的应用。随着早期血运重建的普及,合并CS的STEMI患者在血流动力学相对稳定时启用口服β-受体阻滞剂逐渐成为可能,但其对远期预后的影响尚不清楚。本研究旨在我国...